Leaderboards/chronic myeloid leukemia treatments

chronic myeloid leukemia treatments

Last updated June 11, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Timothy P. Hughes
Royal Adelaide Hospital
90
2
Daniel J. DeAngelo
Dana-Farber Cancer Institute
70
3
Ehab Atallah
Medical College of Wisconsin
60
4
Elias Jabbour
The University of Texas MD Anderson Cancer Center
30
5
H. Kantarjian
The University of Texas MD Anderson Cancer Center
20
6
Carlo Gambacorti‐Passerini
Azienda Ospedaliera San Gerardo
10

Rising Stars Papers

Insufficient data

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
François‐Xavier Mahon
Université de Bordeaux
99
2
David T Yeung
Royal Adelaide Hospital
99
3
Alba Rodríguez-Meira
Broad Institute
90
4
Mohamed El‐Tanani
Al-Ahliyya Amman University
80
5
Neil P. Shah
UCSF Helen Diller Family Comprehensive Cancer Center
70
6
William Shomali
Stanford Medicine
50
7
Stephen Jun Fei Chong
Harvard University
40
8
Jani Huuhtanen
University of Helsinki
30
9
Hjalmar Flygt
Uppsala University Hospital
10

Emerging Leaders Papers

1
Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution
Nature Genetics|2023
139 cit.
2
Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma
Journal of Clinical Investigation|2023
93 cit.
3
Ran GTPase and Its Importance in Cellular Signaling and Malignant Phenotype
International Journal of Molecular Sciences|2023
61 cit.
4
Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia
Nature Communications|2022
51 cit.
5
Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies
Leukemia|2025
6 cit.
6
TIM3 blockade with hypomethylating therapy restores NK and cytotoxic CD4+ T cell activity in patients with AML or MDS
medRxiv|2025
0 cit.

All-Time Leaders

The canon

All-Time Leaders Researchers

1
Andreas Hochhaus
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
99
2
Brian Druker
Howard Hughes Medical Institute
90
3
Marlise R. Luskin
Dana-Farber Cancer Institute
80
4
Moshe Talpaz
University of Michigan
80
5
Hagop M. Kantarjian
The University of Texas MD Anderson Cancer Center
70
6
Claude Preudhomme
Inserm
60
7
Jörge E. Cortes
Augusta University Health
60
8
Giuseppe Saglio
University of Turin
40
9
Joerg Hasford
Ludwig-Maximilians-Universität München
30
10
Dan Jones
The University of Texas MD Anderson Cancer Center
20

All-Time Leaders Papers

1
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Leukemia|2022
3.8k cit.
2
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
New England Journal of Medicine|2002
2k cit.
3
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
Leukemia|2016
849 cit.
4
Acute myeloid leukemia: current progress and future directions
Blood Cancer Journal|2021
750 cit.
5
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Blood|2007
744 cit.
6
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
Haematologica|2010
204 cit.
7
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML
Blood|2004
198 cit.
8
CD4+/CD56+ Hematodermic Tumor
American Journal of Clinical Pathology|2007
172 cit.
9
Third-line therapy for chronic myeloid leukemia: current status and future directions
Journal of Hematology & Oncology|2021
115 cit.
10
RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia
Blood|2007
69 cit.

Reagents for chronic myeloid leukemia treatments

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

Cell Signaling Technology

Thioredoxin 2 (D1C9L) Rabbit Monoclonal Antibody

Cited in 6 papers
#14907$157
View Evidence →

⭐ Recommended

Best all-around

Cell Signaling Technology

Phospho-ALK (Tyr1586) Antibody

Cited in 10 papers
#3343$362
View Evidence →Cell Signaling Technology

Phospho-Stat5 (Tyr694) (C11C5) Rabbit Monoclonal Antibody

Cited in 10 papers
#9359$168
View Evidence →Cell Signaling Technology

Stat5 (D2O6Y) Rabbit Monoclonal Antibody

Cited in 10 papers
#94205$152
View Evidence →

🌟 All-Time

Most validated

Santa Cruz Biotechnology

c-Abl (24-11)

Cited in 20 papers
#sc-23
View Evidence →Cell Signaling Technology

Phospho-Tyrosine Mouse Monoclonal Antibody (P-Tyr-100) (Alexa Fluor® 488 Conjugate)

Cited in 11 papers
#9414$493
View Evidence →Cell Signaling Technology

p56Dok-2 Antibody

Cited in 10 papers
#3914$317
View Evidence →